A dendrimer nanoparticle carrying both a cell-penetrating peptide and an anti-inflammatory peptide improved survival and reduced organ damage in septic mice.
Improved sepsis survivalDual-peptide dendrimer reduced mortality and organ damage in mouse sepsis model
What the researchers found
PAMAM dendrimer nanoparticles decorated with both TAIP (anti-inflammatory peptide) and CPP (cell-penetrating peptide) improved mortality and organ damage in septic mice.
Why it matters
Sepsis kills over 250,000 Americans annually and has no approved targeted therapy. A nanoparticle approach that delivers anti-inflammatory peptides inside cells represents a potential breakthrough.
The numbers in context
TAIP blocks TGFBIp acetylation at K676; CPP-PAMAM-PEG delivery; improved survival/organ damage; suppressed LPS-induced inflammation
How the study worked
Peptide-dendrimer conjugation chemistry; in vitro endothelial cell inflammation assays with LPS; in vivo mouse sepsis survival model with organ damage assessment.
Who was studied
Septic mice and LPS-activated endothelial cells
What this study cannot tell us
Mouse sepsis model with unspecified group sizes; no comparison to standard of care; long-term toxicity of PAMAM dendrimers not assessed; human translation unclear.
How to read the evidence
Preliminary — proof-of-concept animal study with in vitro mechanistic support but no clinical data.
When this study was published
Published in 2020; sepsis therapeutics remain an area of intense unmet need.
The bigger picture
Combining cell-penetrating peptides with therapeutic peptides on nanocarriers is an emerging strategy to overcome the bioavailability problems that plague peptide drugs, particularly for acute conditions like sepsis.
Questions still open
- What is the optimal dosing window for TAIP-dendrimer administration in sepsis?
- Are PAMAM dendrimers safe for systemic administration in humans?
- Could this approach work for other acute inflammatory conditions beyond sepsis?
Common questions
Why is sepsis so hard to treat?
What does the cell-penetrating peptide do?
Read the original research
Dual peptide-dendrimer conjugate inhibits acetylation of transforming growth factor β-induced protein and improves survival in sepsis.
Biomaterials, 246, 120000
Citation
Lee, Wonhwa; Park, Eun Ji; Kwon, Oh Kwang; Kim, Hyelim; Yoo, Youngbum; Kim, Shin-Woo; Seo, Young-Kyo; Kim, In-San; Na, Dong Hee; Bae, Jong-Sup. (2020). Dual peptide-dendrimer conjugate inhibits acetylation of transforming growth factor β-induced protein and improves survival in sepsis.. Biomaterials, 246, 120000. https://doi.org/10.1016/j.biomaterials.2020.120000